Tradjenta
Indications
Linagliptin is FDA-approved (initial U.S. approval 2011) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Within the dipeptidyl peptidase-4 (DPP-4) inhibitor class, linagliptin is distinguished by its predominantly enterohepatic excretion: only about 5% of an administered dose is eliminated unchanged in urine, allowing it to be used at full dose across the entire spectrum of renal function — including end-stage renal disease — without dose adjustment. Cardiovascular and renal safety in high-risk patients was established by the CARMELINA trial; cardiovascular non-inferiority versus a sulfonylurea was established by the CAROLINA trial.
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Type 2 diabetes — glycemic control | Adults (≥18 years) | Adjunct to diet and exercise; mono- or combination | FDA Approved |
| Combination with metformin, sulfonylureas, thiazolidinediones, SGLT2 inhibitors, or insulin | Adults inadequately controlled on monotherapy | Add-on therapy | FDA Approved |
| T2DM with chronic kidney disease (any stage, including ESRD/dialysis) | Adults at any eGFR; no dose adjustment | Mono- or combination (label-supported) | FDA Approved |
| Pediatric type 2 diabetes | Patients <18 years | — | Not Approved |
| Inpatient hyperglycemia management | Hospitalized adults with mild-to-moderate hyperglycemia | Adjunctive (selected cases) | Off-Label |
Linagliptin should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. Within current treatment algorithms, DPP-4 inhibitors generally occupy a third- or fourth-line role behind metformin, GLP-1 receptor agonists, and SGLT2 inhibitors — particularly in patients with established cardiovascular disease, heart failure, or chronic kidney disease, where the latter classes provide organ-protective benefits that DPP-4 inhibitors do not. However, linagliptin’s renal-impairment profile makes it a particularly attractive choice in advanced CKD when a GLP-1 RA or SGLT2i is contraindicated, not tolerated, or when simplicity of dosing without renal monitoring is a clinical priority.
Pediatric T2DM (Evidence: Negative) — Effectiveness was not demonstrated in a 26-week, randomized, double-blind, placebo-controlled trial (NCT03429543) of 157 pediatric patients aged 10 to 17 years with inadequately controlled type 2 diabetes mellitus (current FDA labeling, Section 8.4). Linagliptin is therefore not approved for use in patients younger than 18 years.
Inpatient hyperglycemia (Evidence: Low–Moderate) — Small studies in non-critically ill hospitalized patients suggest acceptable efficacy as an adjunct to basal insulin in selected cases with mild-to-moderate hyperglycemia and adequate beta-cell function; not a replacement for insulin in moderate-to-severe hyperglycemia or in surgical or critical care settings.
Cardiovascular benefit (Evidence: Negative) — CARMELINA established cardiovascular safety but did not demonstrate cardiovascular benefit. Linagliptin should not be selected for the purpose of MACE reduction or kidney-disease modification; GLP-1 receptor agonists and SGLT2 inhibitors are preferred when CV or renal-protective effects are treatment goals.
Dosing
The standard adult dose of linagliptin is 5 mg orally once daily, taken with or without food. Linagliptin is supplied as a single strength (5 mg, light red, round, biconvex tablet debossed “D5”). Unlike other agents in the DPP-4 class, no dose adjustment is recommended based on age, sex, body mass index, race, hepatic impairment, or renal impairment of any severity — including patients with end-stage renal disease on dialysis. Combination with insulin or sulfonylureas warrants pre-emptive dose reduction of those agents to mitigate hypoglycemia.
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| T2DM — adult, normal renal function | 5 mg PO daily | 5 mg PO daily | 5 mg PO daily | No titration required. Take with or without food at the same time daily. Expected HbA1c reduction: ~0.5–0.7%. |
| Renal impairment — any stage (mild, moderate, severe, ESRD on dialysis) | 5 mg PO daily | 5 mg PO daily | 5 mg PO daily | No adjustment required at any eGFR. CARMELINA enrolled patients with eGFR <30 (15% of the linagliptin arm) without dose modification. |
| Hepatic impairment — any severity | 5 mg PO daily | 5 mg PO daily | 5 mg PO daily | No adjustment required across mild, moderate, and severe (Child-Pugh) hepatic impairment without clinically meaningful PK changes. |
| Concurrent insulin or sulfonylurea | 5 mg PO daily | 5 mg PO daily | 5 mg PO daily | Reduce insulin or sulfonylurea dose at initiation to reduce hypoglycemia risk. Hypoglycemia incidence (≤54 mg/dL) rises to 8.1% with metformin + SU vs 5.3% placebo + metformin + SU. |
| Concurrent strong P-gp / CYP3A4 inducer (e.g., rifampin) | Avoid combination | — | — | Linagliptin exposure is reduced; efficacy may be compromised. Use of alternative antihyperglycemic therapy is strongly recommended (FDA labeling). |
| Older adults (≥65 years) | 5 mg PO daily | 5 mg PO daily | 5 mg PO daily | No age-based adjustment. Reassuring data from CARMELINA in patients ≥75 years. |
| Missed dose | Take as soon as remembered the same day | If almost time for next dose, skip and resume regular schedule. Do not double dose. | ||
Linagliptin’s predominantly biliary clearance is its defining clinical advantage. Sitagliptin requires dose reduction at eGFR <45 and again at eGFR <30; saxagliptin requires reduction at eGFR ≤45; alogliptin requires multiple dose reductions through CKD progression. Linagliptin is the only DPP-4 inhibitor that can be initiated and continued at full dose across all CKD stages, including dialysis-dependent ESRD, without monitoring or dose changes. Hemodialysis or peritoneal dialysis is unlikely to remove a clinically meaningful amount of drug.
Linagliptin and sitagliptin both demonstrated cardiovascular safety in dedicated outcomes trials (CARMELINA, TECOS). Saxagliptin and alogliptin showed an excess of heart-failure hospitalization in SAVOR-TIMI 53 and EXAMINE respectively, leading to FDA labeling changes. Among DPP-4 inhibitors, linagliptin uniquely combines once-daily dosing, no required dose adjustment for any organ impairment, neutral cardiovascular safety, and a low intrinsic risk of hypoglycemia — making it a frequent choice in older adults and patients with CKD.
Pharmacology
Mechanism of Action
Linagliptin is a competitive, reversible inhibitor of dipeptidyl peptidase-4 (DPP-4), the enzyme that degrades the endogenous incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). At the 5 mg therapeutic dose, linagliptin produces greater than 80% inhibition of plasma DPP-4 activity over 24 hours, prolonging the post-prandial action of these incretins and producing roughly a two- to three-fold increase in active GLP-1 concentrations. The downstream consequences include glucose-dependent stimulation of insulin secretion from pancreatic beta cells and suppression of inappropriately elevated post-prandial glucagon release from alpha cells. Because the insulinotropic effect is glucose-dependent, linagliptin used as monotherapy carries a low intrinsic risk of hypoglycemia.
Linagliptin exhibits non-linear pharmacokinetics driven by target-mediated drug disposition: high-affinity, saturable binding to DPP-4 produces concentration-dependent plasma protein binding and an unusually long terminal half-life (greater than 100 hours). The clinically relevant accumulation half-life — the parameter that governs once-daily dosing — is approximately 12 hours, allowing rapid attainment of steady state within 2 to 4 days. Linagliptin is weight-neutral, with no meaningful effect on gastric emptying or appetite. Expected HbA1c reduction is approximately 0.5–0.7% as monotherapy or add-on therapy, smaller than that achieved with GLP-1 receptor agonists or SGLT2 inhibitors. The CARMELINA trial confirmed cardiovascular and renal safety in a high-risk T2DM population but did not demonstrate cardiovascular or renoprotective benefit, distinguishing this class from GLP-1 receptor agonists and SGLT2 inhibitors.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Bioavailability ~30%; Tmax ~1.5 hours; high-fat meal reduces Cmax ~15% (not clinically relevant) | Low absolute bioavailability is reproducible. May be administered with or without food. |
| Distribution | Vd ~1,110 L; concentration-dependent protein binding (~99% at 1 nmol/L, 75–89% at ≥30 nmol/L, 70–80% at therapeutic levels reflecting DPP-4 saturation) | Extensive tissue distribution. Saturation of DPP-4 binding underlies the pharmacokinetic non-linearity at therapeutic doses. |
| Metabolism | Minor hepatic metabolism (CYP3A4); the majority of drug eliminated as parent compound. Pharmacologically inactive S-3-hydroxypiperidinyl metabolite (CD 1790) accounts for ~17% of drug-related compounds in plasma | Minor PK changes only with strong CYP3A4 inducers. Not a clinically meaningful CYP inhibitor. |
| Elimination | Predominantly enterohepatic / fecal (~85%); only ~5% renal excretion of unchanged drug; effective accumulation t½ ~12 h, terminal t½ >100 h | No dose adjustment required at any degree of renal impairment, including ESRD on dialysis. Removal by hemodialysis or peritoneal dialysis is unlikely. |
Side Effects
Linagliptin is generally well tolerated, with overall adverse-reaction rates in placebo-controlled trials similar to placebo when used as monotherapy or with metformin. Frequencies below are derived from the FDA-approved labeling pooled placebo-controlled trial data (14 trials; n=3,625 linagliptin vs n=2,176 placebo), the CARMELINA cardiovascular and renal outcomes trial, and the CAROLINA active-comparator trial versus glimepiride. The most clinically relevant adverse reactions cluster into hypoglycemia (when combined with insulin or sulfonylureas), upper respiratory tract symptoms, and class-related immunologic, pancreatic, and joint events. Hypoglycemia rates below use the FDA-standardized definition of plasma glucose ≤54 mg/dL.
| Adverse Effect | Incidence (Comparator) | Clinical Note |
|---|---|---|
| Hypoglycemia (≤54 mg/dL) with basal insulin (52 weeks) | 19.8% (21.6%) | Notably no excess vs placebo + insulin. Severe hypoglycemia 1.7% vs 1.1%. |
| Hypoglycemia (any, vs glimepiride monotherapy in CAROLINA) | 10.6% (37.7%) | Linagliptin had ~77% lower risk than glimepiride over 6.3 years (HR 0.23, 95% CI 0.21–0.26). |
| Adverse Effect | Incidence (Placebo) | Clinical Note |
|---|---|---|
| Hypoglycemia (≤54 mg/dL) with metformin + sulfonylurea | 8.1% (5.3%) | Severe hypoglycemia 0.6% vs 0.8% — actually numerically lower with linagliptin. |
| Nasopharyngitis (pooled placebo-controlled trials) | 7.0% (6.1%) | Mild and self-limited in most patients; symptomatic care typically sufficient. |
| Diarrhea (pooled placebo-controlled trials) | 3.3% (3.0%) | Largely attributable to metformin co-administration. |
| Cough (pooled placebo-controlled trials) | 2.1% (1.4%) | Usually mild; consider alternate causes if persistent. |
| Hyperuricemia (laboratory finding) | 2.7% (1.3%) | Modest increase in uric acid above placebo. Routine monitoring not required. |
| Urinary tract infection (when added to sulfonylurea) | 3.1% (0%) | Reported in the 18-week SU add-on trial. Standard UTI evaluation and treatment. |
| Hypoglycemia (≤54 mg/dL) with sulfonylurea (18 weeks) | 1.9% (1.2%) | No severe hypoglycemia in either group in this trial. |
| Severe hypoglycemia (vs glimepiride in CAROLINA, 6.3 yr) | 0.3% (2.2%) | Markedly lower than glimepiride over 6.3 years follow-up. |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Acute pancreatitis (including fatal) | CARMELINA: 0.3% vs 0.1% placebo (2 fatal cases on linagliptin). Pooled program: 15.2 vs 3.7 cases per 10,000 patient-years | Any time after initiation | Discontinue immediately if suspected; check lipase; do not restart if confirmed. |
| Bullous pemphigoid | CARMELINA: 7 (0.2%) on linagliptin vs 0 placebo; 3 hospitalizations in linagliptin arm | Months to years | Discontinue; dermatology referral; topical or systemic immunosuppressives often needed. |
| Anaphylaxis / angioedema / urticaria | Postmarketing (rare) | Within first 3 months (some after first dose) | Discontinue permanently; emergency care; contraindication to re-challenge. |
| Bronchial hyperreactivity | Postmarketing (rare); contraindication if prior reaction | Variable | Discontinue; alternative antihyperglycemic therapy. Caution in known reactive airways disease. |
| Exfoliative skin reactions / Stevens-Johnson syndrome | Postmarketing (rare) | Within first 3 months | Discontinue immediately; dermatology and emergency referral. |
| Severe and disabling arthralgia | Postmarketing (rare); class effect | 1 day to years | Discontinue; symptoms typically resolve. Avoid re-challenge with any DPP-4 inhibitor. |
| Lipase elevation (asymptomatic) | Lipase >3× ULN: 8.2% vs 1.7% placebo (24-week albuminuria trial) | Weeks | Clinical significance unclear in absence of pancreatitis symptoms; investigate if symptomatic. |
| Rhabdomyolysis | Postmarketing (rare) | Variable | Investigate severe myalgia or weakness; check CK; discontinue if confirmed. |
| Heart failure (class concern) | No excess in CARMELINA (HHF HR 0.90, 95% CI 0.74–1.08) | Variable | Consider risks/benefits in patients with prior HF; discontinue if HF develops. |
| Severe hypoglycemia (with insulin / SU) | With basal insulin: 1.7% vs 1.1% placebo. CAROLINA: 0.3% vs 2.2% glimepiride | Days–weeks | Pre-emptively reduce insulin or SU dose. Educate on recognition and glucagon use. |
| Reason for Discontinuation | Pattern | Context |
|---|---|---|
| Hypersensitivity / skin reactions | Rare but immediate | Onset typically within first 3 months. Permanent contraindication to re-challenge. |
| Hypoglycemia in combination therapy | Variable | Often resolved by reducing insulin or sulfonylurea rather than stopping linagliptin. |
| Severe arthralgia | Rare | Resolves on discontinuation. Consider as cause of new joint pain in any DPP-4 inhibitor user. |
| Bullous pemphigoid | Rare | Approximately 0.2% in CARMELINA; resolves on discontinuation with appropriate dermatologic management. |
| Lack of glycemic efficacy | Variable | Modest HbA1c reduction (~0.5–0.7%) may be insufficient when targets are not met; switch to GLP-1 RA or SGLT2i often considered. |
Three distinctive DPP-4-class adverse events deserve clinical vigilance: severe arthralgia (consider as a cause of new or worsening joint pain regardless of drug duration; FDA Drug Safety Communication 2015), bullous pemphigoid (subepidermal blistering disorder; in CARMELINA reported in 0.2% of linagliptin-treated patients vs 0% on placebo; counsel patients to report new blisters or erosions), and hypersensitivity reactions including SJS (most often within the first 3 months). Each requires immediate discontinuation; arthralgia and bullous pemphigoid frequently resolve following drug withdrawal.
Drug Interactions
Linagliptin has a clean pharmacokinetic interaction profile. It undergoes minimal hepatic metabolism (small contribution from CYP3A4), is not a meaningful CYP inhibitor or inducer, and demonstrated no clinically relevant pharmacokinetic interaction with metformin, glyburide, simvastatin, pioglitazone, warfarin, oral contraceptives, or digoxin in dedicated studies. The single notable pharmacokinetic interaction concerns strong P-gp / CYP3A4 inducers, which substantially reduce linagliptin exposure. Beyond that, the clinically significant interactions are pharmacodynamic synergy with other glucose-lowering agents.
Monitoring
Linagliptin has the simplest monitoring profile within the DPP-4 inhibitor class. Because no dose adjustment is required for renal or hepatic function, routine monitoring of these parameters is driven only by general diabetes care guidelines rather than by linagliptin itself. The highest-yield surveillance points are glycemic response and symptom-driven monitoring for class-specific adverse events: pancreatitis, hypersensitivity, arthralgia, pemphigoid, and heart-failure symptoms.
-
HbA1c
Every 3 months until at goal, then every 6 months
Routine Expected reduction approximately 0.5–0.7%. If targets are not met after 3 months, escalate by adding another agent — linagliptin has no higher dose to titrate to. -
Renal Function (eGFR)
Per general diabetes care; not required for linagliptin dosing
Routine Linagliptin requires no dose adjustment at any eGFR. Standard diabetes monitoring (annual eGFR and urine albumin–creatinine ratio) still applies. -
Self-Monitored or CGM
Patient-directed; intensified if on insulin or SU
Routine Monotherapy carries minimal hypoglycemia risk. Combination with insulin or sulfonylureas warrants more frequent monitoring during titration. -
Pancreatitis Symptoms
Each visit; immediate review if symptomatic
Trigger-based Severe persistent epigastric pain radiating to the back warrants discontinuation, lipase measurement, and imaging. Routine asymptomatic lipase screening is not recommended (linagliptin can cause asymptomatic lipase elevation). -
Joint Symptoms
Each visit; review at any new arthralgia
Trigger-based Severe and disabling arthralgia is a recognized DPP-4 class effect (FDA Drug Safety Communication, 2015). Onset can range from days to years. Resolves on discontinuation. -
Skin / Mucosal Examination
Each visit; review with new lesions
Trigger-based Counsel patients to report new blisters, erosions, mucosal lesions, or widespread rash. Bullous pemphigoid was reported in 0.2% of CARMELINA participants on linagliptin (vs 0% placebo) and warrants immediate discontinuation. -
Heart Failure Symptoms
Each visit (esp. patients with prior HF or CKD)
Trigger-based CARMELINA did not show increased HF risk for linagliptin specifically (HHF HR 0.90, 95% CI 0.74–1.08), but the FDA labeling notes class concern. Investigate dyspnea, lower-extremity edema, or weight gain. -
Respiratory Symptoms
Each visit
Trigger-based Bronchial hyperreactivity has been reported postmarketing. Use caution in patients with reactive airways disease and discontinue if symptoms develop after initiation. -
Body Weight
Each visit
Routine Linagliptin is weight-neutral or modestly weight-lowering (mean −1.1 to −1.4 kg over 1–2 years vs glimepiride). Significant weight gain on therapy may indicate inadequate diabetes control or alternate drug effects. -
Lipid Panel & BP
Per CV risk management guidelines
Routine Linagliptin has no meaningful effect on lipid profile or blood pressure. Standard CV risk surveillance still applies.
Contraindications & Cautions
An FDA Drug Safety Communication (August 2015) requires DPP-4 inhibitor labeling to warn that this class can cause severe and disabling arthralgia. Onset ranges from one day to years after starting therapy. Symptoms typically resolve upon discontinuation, and recurrence has been reported when the same or a different DPP-4 inhibitor is restarted. Clinicians should consider DPP-4 inhibitors as a possible cause of unexplained or severe joint pain and discontinue the drug if implicated.
Absolute Contraindications
- Prior serious hypersensitivity reaction to linagliptin — anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity (FDA-labeled contraindication).
- Type 1 diabetes mellitus — linagliptin is not effective for absolute insulin deficiency.
- Diabetic ketoacidosis — insulin is the cornerstone of treatment.
Relative Contraindications (Specialist Input Recommended)
- History of pancreatitis — linagliptin has not been studied in this population per FDA labeling. Risk-benefit discussion advised; alternative classes generally preferred.
- History of severe arthralgia on another DPP-4 inhibitor — class re-challenge can precipitate symptoms; switch class if possible.
- History of bullous pemphigoid on another DPP-4 inhibitor — avoid the class.
- Concurrent strong P-gp / CYP3A4 inducer (rifampin, phenytoin, carbamazepine, St. John’s wort) — efficacy is reduced; use alternative antihyperglycemic therapy.
- Pregnancy — limited human data. Insulin is the preferred therapy; use linagliptin only if benefit clearly outweighs risk.
Use with Caution
- Risk factors for heart failure — prior HF or significant renal impairment; assess risks/benefits before initiation and monitor for HF symptoms.
- Concomitant insulin or sulfonylureas — adjust those agents downward to mitigate hypoglycemia.
- Reactive airways disease (asthma, COPD) — bronchial hyperreactivity has been reported; remain vigilant for new respiratory symptoms.
- Older adults with multiple comorbidities — heightened vigilance for hypoglycemia in combination therapy. CARMELINA showed reassuring outcomes in patients ≥75 years.
- Pre-procedural fasting / acute illness — temporary hold reasonable when oral intake is interrupted.
- Breastfeeding — animal data show milk excretion; no human data. Balance maternal benefit against unknown infant exposure.
Patient Counselling
Purpose of Therapy
Explain that linagliptin is an oral once-daily medication that helps the body release more insulin and lower glucagon when blood sugar is high — but only when blood sugar is high — so it does not usually cause low blood sugar on its own. It typically lowers HbA1c by about 0.5–0.7 percentage points and is weight-neutral. It does not provide additional protection against heart attacks or kidney decline beyond what blood-sugar control offers. A practical advantage is that it can be used at the same dose regardless of how well the kidneys or liver are working — the dose never needs to change for those reasons.
How to Take
Take one 5 mg tablet by mouth at the same time every day, with or without food. The tablet should be swallowed whole; do not split or crush. If a dose is missed, take it as soon as remembered the same day. If the next dose is almost due, skip the missed dose and resume the regular schedule — do not double up. Store at room temperature, away from moisture. Keep out of reach of children.
Sources
- U.S. Food and Drug Administration. Tradjenta (linagliptin) prescribing information. Boehringer Ingelheim Pharmaceuticals; revised June 2023. accessdata.fda.gov Definitive U.S. labeling — primary source for the renal-function-independent dosing recommendation, adverse-reaction tables (Tables 1 and 2), CARMELINA-derived bullous pemphigoid and pancreatitis incidence figures, pediatric trial result, and class-warning sections (5.1–5.6).
- European Medicines Agency. Trajenta (linagliptin) Summary of Product Characteristics. ema.europa.eu European labeling reference; useful cross-check for non-US jurisdictions.
- U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. August 28, 2015. fda.gov Source document for the class-wide arthralgia warning incorporated into all DPP-4 inhibitor labels, including linagliptin.
- Rosenstock J, Perkovic V, Johansen OE, et al; CARMELINA Investigators. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321(1):69–79. doi.org/10.1001/jama.2018.18269 Pivotal cardiovascular and renal outcomes trial (n=6,979; 3P-MACE HR 1.02, 95% CI 0.89–1.17; median follow-up 2.2 years) establishing CV non-inferiority for linagliptin in high-risk patients including those with eGFR <30 mL/min/1.73 m².
- Rosenstock J, Kahn SE, Johansen OE, et al; CAROLINA Investigators. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA. 2019;322(12):1155–1166. doi.org/10.1001/jama.2019.13772 First head-to-head DPP-4 inhibitor vs sulfonylurea CV outcomes trial (n=6,033; median 6.3 yr); 3P-MACE HR 0.98 (95.47% CI 0.84–1.14); hypoglycemia HR 0.23 (95% CI 0.21–0.26) favoring linagliptin.
- McGuire DK, Alexander JH, Johansen OE, et al; CARMELINA Investigators. Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA. Circulation. 2019;139(3):351–361. doi.org/10.1161/CIRCULATIONAHA.118.038352 Pre-specified CARMELINA HF analysis: hospitalization for heart failure HR 0.90 (95% CI 0.74–1.08), distinguishing linagliptin from saxagliptin and alogliptin.
- Perkovic V, Toto R, Cooper ME, et al; CARMELINA Investigators. Effects of linagliptin on cardiovascular and kidney outcomes in people with normal and reduced kidney function: secondary analysis of the CARMELINA randomized trial. Diabetes Care. 2020;43(8):1803–1812. doi.org/10.2337/dc20-0279 Confirms cardiovascular and renal safety of linagliptin across the full eGFR spectrum (≥60 down to <30), supporting unrestricted use across CKD stages.
- Marx N, Kolkailah AA, Rosenstock J, et al. Hypoglycemia and cardiovascular outcomes in the CARMELINA and CAROLINA trials of linagliptin: a secondary analysis of randomized clinical trials. JAMA Cardiol. 2024;9(2):182–187. doi.org/10.1001/jamacardio.2023.4602 Demonstrates the hypoglycemia–cardiovascular event linkage and reinforces the practical advantage of linagliptin’s low hypoglycemia profile.
- American Diabetes Association Professional Practice Committee. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes. Diabetes Care. Updated annually. diabetesjournals.org/care Authoritative U.S. guidance; positions DPP-4 inhibitors as third- or fourth-line agents and does not recommend combination with GLP-1 receptor agonists.
- Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–2786. doi.org/10.2337/dci22-0034 ADA-EASD consensus shaping the relative role of DPP-4 inhibitors versus GLP-1 RAs and SGLT2 inhibitors in T2DM care pathways.
- Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102(5S):S1–S127. kdigo.org Reference for DPP-4 inhibitor selection in patients with diabetes and CKD; highlights linagliptin’s renal-function-independent dosing as a practical advantage in advanced CKD.
- Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740–756. doi.org/10.1016/j.cmet.2018.03.001 Comprehensive review of incretin biology underlying both DPP-4 inhibitor and GLP-1 receptor agonist therapy.
- Eckhardt M, Langkopf E, Mark M, et al. 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem. 2007;50(26):6450–6453. doi.org/10.1021/jm701280z Original medicinal-chemistry paper describing the discovery of linagliptin (BI 1356); xanthine-based scaffold distinguishes linagliptin pharmacologically from sitagliptin.
- Heise T, Graefe-Mody EU, Hüttner S, Ring A, Trommeshauser D, Dugi KA. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab. 2009;11(8):786–794. doi.org/10.1111/j.1463-1326.2009.01046.x Foundational PK study supporting once-daily dosing: bioavailability ~30%, accumulation half-life ~12 hours, >80% DPP-4 inhibition over 24 hours at the 5 mg dose.
- Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab. 2011;13(10):939–946. doi.org/10.1111/j.1463-1326.2011.01458.x Foundational study supporting renal-function-independent dosing: linagliptin exposure is minimally affected even in severe renal impairment, including ESRD on dialysis.
- Graefe-Mody U, Rose P, Retlich S, et al. Pharmacokinetics of linagliptin in subjects with hepatic impairment. Br J Clin Pharmacol. 2012;74(1):75–85. doi.org/10.1111/j.1365-2125.2012.04173.x Confirms that no dose adjustment is required across mild, moderate, and severe (Child-Pugh) hepatic impairment.